1
|
Wendel AF, Otchwemah R, Layer-Nicolaou F, Mattner F, Tellez-Castillo CJ, Skov R, Oberländer H, Werner G, Strommenger B. Investigating a possible link between antiseptic treatment and the increased occurrence of daptomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2023; 29:1334.e1-1334.e6. [PMID: 37321393 DOI: 10.1016/j.cmi.2023.06.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 05/26/2023] [Accepted: 06/06/2023] [Indexed: 06/17/2023]
Abstract
OBJECTIVES Because of a steady increase in the detection of daptomycin-resistant (DAP-R) Staphylococcus aureus at three medical centres in Cologne, Germany, molecular surveillance was established from June 2016 to June 2018 to investigate the causes of the emergence and spread of respective isolates. Seventy-five S. aureus isolates, both DAP-R and DAP-susceptible, were collected from 42 patients for further analysis. METHODS Broth microdilution was used to determine the MICs for DAP and polyhexamethylene biguanide/polyhexanide (PHMB). To investigate the effect of PHMB on the development of DAP resistance, we performed selection experiments with PHMB. All isolates studied were subjected to whole-genome sequencing. Epidemiological, clinical, microbiological and molecular data were analysed comparatively. RESULTS Acquisition of DAP resistance was mainly observed in patients with acute and chronic wounds (40/42, 96.2%) treated with antiseptic (32/42, 76.2%) rather than systemic antibiotic therapy using DAP or vancomycin (7/42, 16.7%). DAP-R S. aureus had a diverse genetic background; however, within individual patients, isolates were closely related. At least three potential transmission events were detected. Most DAP-R isolates had concomitant elevated MICs for PHMB (50/54, 92.6%), and in vitro selection experiments confirmed that PHMB treatment is capable of generating DAP resistance. DAP resistance could be linked to 12 different polymorphisms in the mprF gene in the majority of clinical isolates (52/54, 96.3%) as well as in all in vitro selected strains. DISCUSSION DAP resistance in S. aureus can occur independently of prior antibiotic therapy and can be selected by PHMB. Therefore, wound treatment with PHMB may trigger individual resistance development associated with gain-of-function mutations in the mprF gene.
Collapse
Affiliation(s)
- Andreas F Wendel
- Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany; Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany
| | - Robin Otchwemah
- Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany; Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany
| | - Franziska Layer-Nicolaou
- Robert Koch Institute, Department of Infectious Diseases, Division 'Nosocomial Pathogens and Antibiotic Resistances', National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany
| | - Frauke Mattner
- Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany; Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany
| | | | - Robert Skov
- Department of Clinical Microbiology, MVZ Synlab Leverkusen GmbH, Köln-Merheim, Germany
| | - Henrik Oberländer
- Department of Plastic Surgery, Hand Surgery, Burn Centre, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany
| | - Guido Werner
- Robert Koch Institute, Department of Infectious Diseases, Division 'Nosocomial Pathogens and Antibiotic Resistances', National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany
| | - Birgit Strommenger
- Robert Koch Institute, Department of Infectious Diseases, Division 'Nosocomial Pathogens and Antibiotic Resistances', National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany.
| |
Collapse
|
2
|
Li G, Walker MJ, De Oliveira DMP. Vancomycin Resistance in Enterococcus and Staphylococcus aureus. Microorganisms 2022; 11:microorganisms11010024. [PMID: 36677316 PMCID: PMC9866002 DOI: 10.3390/microorganisms11010024] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 12/19/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022] Open
Abstract
Enterococcus faecalis, Enterococcus faecium and Staphylococcus aureus are both common commensals and major opportunistic human pathogens. In recent decades, these bacteria have acquired broad resistance to several major classes of antibiotics, including commonly employed glycopeptides. Exemplified by resistance to vancomycin, glycopeptide resistance is mediated through intrinsic gene mutations, and/or transferrable van resistance gene cassette-carrying mobile genetic elements. Here, this review will discuss the epidemiology of vancomycin-resistant Enterococcus and S. aureus in healthcare, community, and agricultural settings, explore vancomycin resistance in the context of van and non-van mediated resistance development and provide insights into alternative therapeutic approaches aimed at treating drug-resistant Enterococcus and S. aureus infections.
Collapse
|
3
|
Cazavet J, Bounes FV, Ruiz S, Seguin T, Crognier L, Rouget A, Fourcade O, Minville V, Conil JM, Georges B. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis 2019; 39:527-538. [PMID: 31853741 DOI: 10.1007/s10096-019-03754-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Accepted: 10/27/2019] [Indexed: 11/30/2022]
Abstract
Linezolid is an antibiotic used against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Its primary adverse effect is haematotoxicity. The objective of this study was to analyse the risk factors for onset of thrombocytopenia in critically ill patients treated with linezolid. This was a retrospective, single-centre study of 72 patients. Platelets were measured from D0 to D20 after the start of treatment. The risk factors for thrombocytopenia were identified using a multivariate logistic regression analysis following a Monte Carlo simulation. Following ROC curve analysis, a baseline platelet count lower than 108 × 109/L and a Cmin higher than 4 mg/L, with respective odds ratios of 117 (95% CI [97-206]) and 3 (95% CI [1.5-6.2]) in the simulated population, were identified as risk factors. Among the source population patients combining these 2 factors, a significantly higher number developed thrombocytopenia (66.7% vs. 33.3%, p = 0.0042). A baseline platelet count lower than 108 × 109/L and a Cmin higher than 4 mg/L are risk factors for the onset of thrombocytopenia in critically ill patients treated with linezolid.
Collapse
Affiliation(s)
- Julien Cazavet
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Fanny Vardon Bounes
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Stéphanie Ruiz
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Thierry Seguin
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Laure Crognier
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Antoine Rouget
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Olivier Fourcade
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Vincent Minville
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Jean-Marie Conil
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France.,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France
| | - Bernard Georges
- Intensive Care Unit, University Hospital of Toulouse, 1 Avenue Jean Poulhès, 31059, Toulouse Cedex 9, France. .,Department of Anesthesiology and Critical Care, University Hospital of Toulouse, TSA 50032, 31059, Toulouse Cedex 9, France.
| |
Collapse
|
4
|
Antibiotic resistance patterns of Staphylococcus aureus: A multi center study from India. Microb Pathog 2016; 98:167-70. [DOI: 10.1016/j.micpath.2016.07.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 07/10/2016] [Accepted: 07/13/2016] [Indexed: 11/21/2022]
|
5
|
Snowden R, Harrington H, Morrill K, Jeane L, Garrity J, Orian M, Lopez E, Rezaie S, Hassberger K, Familoni D, Moore J, Virdee K, Albornoz-Sanchez L, Walker M, Cavins J, Russell T, Guse E, Reker M, Tschudy O, Wolf J, True T, Ukaegbu O, Ahaghotu E, Jones A, Polanco S, Rochon Y, Waters R, Langland J. A Comparison of the Anti-Staphylococcus aureus Activity of Extracts from Commonly Used Medicinal Plants. J Altern Complement Med 2014; 20:375-82. [DOI: 10.1089/acm.2013.0036] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Affiliation(s)
- Rebecca Snowden
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Heather Harrington
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
- Biodesign Institute, Arizona State University, Tempe, AZ
| | - Kira Morrill
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - LaDeana Jeane
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Joan Garrity
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Michael Orian
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Eric Lopez
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Saman Rezaie
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Kelly Hassberger
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Damilola Familoni
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Jessica Moore
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Kulveen Virdee
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Leah Albornoz-Sanchez
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Michael Walker
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Jami Cavins
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Tonyelle Russell
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Emily Guse
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Mary Reker
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Onyria Tschudy
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Jeremy Wolf
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Teresa True
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Oluchi Ukaegbu
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Ezenwanyi Ahaghotu
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Ana Jones
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Sara Polanco
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
| | - Yvan Rochon
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
- Herbal Vitality, Inc., Sedona, AZ
| | - Robert Waters
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
- Biodesign Institute, Arizona State University, Tempe, AZ
| | - Jeffrey Langland
- Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, AZ
- Biodesign Institute, Arizona State University, Tempe, AZ
| |
Collapse
|
6
|
Memmel E, Homann A, Oelschlaeger TA, Seibel J. Metabolic glycoengineering of Staphylococcus aureus reduces its adherence to human T24 bladder carcinoma cells. Chem Commun (Camb) 2014; 49:7301-3. [PMID: 23852343 DOI: 10.1039/c3cc43424a] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The Gram-positive bacterium Staphylococcus aureus is a human pathogen increasingly causing severe infections, especially in hospital environments. Moreover, strains which are resistant against various types of antibiotics are developing and spreading widely as in the case of the community-acquired MRSA (methicillin resistant S. aureus). In this study metabolic glycoengineering with N-azidoacetyl-glucosamine (GlcNAz) has been successfully applied to S. aureus for the first time. The following bioorthogonal Mendal-Sharpless-Huisgen click reaction between the azido-functionalized S. aureus cells and alkyne dyes enabled staining of these bacteria and reduced their adherence to human T24 bladder carcinoma cells by 48%. The results are of urgent interest to study S. aureus infections.
Collapse
Affiliation(s)
- Elisabeth Memmel
- Institute of Organic Chemistry, Julius-Maximilians-University Würzburg, Am Hubland, 97074 Würzburg, Germany
| | | | | | | |
Collapse
|
7
|
Kurosu M, Siricilla S, Mitachi K. Advances in MRSA drug discovery: where are we and where do we need to be? Expert Opin Drug Discov 2013; 8:1095-116. [PMID: 23829425 DOI: 10.1517/17460441.2013.807246] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Methicillin-resistant Staphylococcus aureus (MRSA) have been on the increase during the past decade, due to the steady growth of the elderly and immunocompromised patients, and the emergence of multidrug-resistant (MDR) bacterial strains. Although there are a limited number of anti-MRSA drugs available, a number of different combination antimicrobial drug regimens have been used to treat serious MRSA infections. Thus, the addition of several new antistaphylococcal drugs into clinical practice should broaden clinician's therapeutic options. As MRSA is one of the most common and problematic bacteria associated with increasing antimicrobial resistance, continuous efforts for the discovery of lead compounds as well as development of alternative therapies and faster diagnostics are required. AREAS COVERED This article summarizes the FDA-approved drugs to treat MRSA infections, the drugs in clinical trials, and the drug leads for MRSA and related Gram-positive bacterial infections. In addition, the article discusses the mode of action of antistaphylococcal molecules and the resistant mechanisms of some molecules. EXPERT OPINION The number of pipeline drugs presently undergoing clinical trials is not particularly encouraging. There are limited and rather expensive therapeutic options for MRSA infections in the critically ill. Further research efforts are required for effective phage therapy on MRSA infections in clinical use, which seem to be attractive therapeutic options for the future.
Collapse
Affiliation(s)
- Michio Kurosu
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, 881 Madison Avenue, Memphis, TN 38163, USA.
| | | | | |
Collapse
|
8
|
Paknikar SS, Narayana S. Newer antibacterials in therapy and clinical trials. NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES 2012. [PMID: 23181224 PMCID: PMC3503371 DOI: 10.4103/1947-2714.103312] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In order to deal with the rising problem of antibiotic resistance, newer antibacterials are being discovered and added to existing pool. Since the year 2000, however, only four new classes of antibacterials have been discovered. These include the oxazolidinones, glycolipopeptides, glycolipodepepsipeptide and pleuromutilins. Newer drugs were added to existing classes of antibiotics, such as streptogramins, quinolones, beta-lactam antibiotics, and macrolide-, tetracycline- and trimethoprim-related drugs. Most of the antibacterials are directed against resistant S. aureus infections, with very few against resistant gram-negative infections. The following article reviews the antibacterials approved by the FDA after the year 2000 as well as some of those in clinical trials. Data was obtained through a literature search via Pubmed and google as well as a detailed search of our library database.
Collapse
|
9
|
Mode-of-action studies of the novel bisquaternary bisnaphthalimide MT02 against Staphylococcus aureus. Antimicrob Agents Chemother 2010; 55:311-20. [PMID: 20937782 DOI: 10.1128/aac.00586-10] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Screening of various bisquaternary bisnaphthalimides against a variety of human pathogens revealed one compound, designated MT02, with strong inhibitory effects against Gram-positive bacteria. The MICs ranged from 0.31 μg/ml against community-acquired methicillin-resistant Staphylococcus aureus (MRSA) lineage USA300 to 20 μg/ml against Streptococcus pneumoniae. Radioactive whole-cell labeling experiments indicated a strong impact of MT02 on bacterial DNA replication. DNA microarray studies generated a transcriptional signature characterized by stronger expression of genes involved in DNA metabolism, DNA replication, SOS response, and transport of positively charged compounds. Furthermore, surface plasmon resonance and gel retardation experiments demonstrated direct binding of MT02 to DNA in a concentration-dependent, reversible, and non-sequence-specific manner. The data presented suggest that the bisquaternary bisnaphthalimide MT02 exerts anti-Gram-positive activity by binding to DNA and thereby preventing appropriate DNA replication.
Collapse
|